The original rise of Sildenafil presented a massive chance for investors , but its period has expired , creating a complex landscape. Generic versions have appeared in the arena, diminishing revenues and putting pressure on profit percentages . While major drug companies continue a foothold in this sector , the potential seems ambiguous by intense